Pemetrexed in the treatment of selected solid tumors

Alex A. Adjei

doi:10.1016/s0093-7754(02)70216-9

Pemetrexed in the treatment of selected solid tumors

Alex A. Adjei

Medical Oncology

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

The novel agent pemetrexed inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Significant activity has been seen in completed phase II trials of pemetrexed in non-small cell lung cancer and breast cancer. Pemetrexed is also active in combination with other agents such as gemcitabine, cisplatin, and carboplatin. In addition, this agent shows promising activity in bladder, head and neck, esophageal, renal, and cervical carcinomas. Preliminary results of studies in these tumor types are reviewed.

Original language	English (US)
Pages (from-to)	50-53
Number of pages	4
Journal	Seminars in oncology
Volume	29
Issue number	2 SUPPL. 5
DOIs	https://doi.org/10.1016/s0093-7754(02)70216-9
State	Published - 2002

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/s0093-7754(02)70216-9

Cite this

@article{e7c32966376443d8959193740b62e5fd,

title = "Pemetrexed in the treatment of selected solid tumors",

abstract = "The novel agent pemetrexed inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Significant activity has been seen in completed phase II trials of pemetrexed in non-small cell lung cancer and breast cancer. Pemetrexed is also active in combination with other agents such as gemcitabine, cisplatin, and carboplatin. In addition, this agent shows promising activity in bladder, head and neck, esophageal, renal, and cervical carcinomas. Preliminary results of studies in these tumor types are reviewed.",

author = "Adjei, \{Alex A.\}",

year = "2002",

doi = "10.1016/s0093-7754(02)70216-9",

language = "English (US)",

volume = "29",

pages = "50--53",

journal = "Seminars in oncology",

issn = "0093-7754",

publisher = "W.B. Saunders",

number = "2 SUPPL. 5",

}

TY - JOUR

T1 - Pemetrexed in the treatment of selected solid tumors

AU - Adjei, Alex A.

PY - 2002

Y1 - 2002

N2 - The novel agent pemetrexed inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Significant activity has been seen in completed phase II trials of pemetrexed in non-small cell lung cancer and breast cancer. Pemetrexed is also active in combination with other agents such as gemcitabine, cisplatin, and carboplatin. In addition, this agent shows promising activity in bladder, head and neck, esophageal, renal, and cervical carcinomas. Preliminary results of studies in these tumor types are reviewed.

AB - The novel agent pemetrexed inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Significant activity has been seen in completed phase II trials of pemetrexed in non-small cell lung cancer and breast cancer. Pemetrexed is also active in combination with other agents such as gemcitabine, cisplatin, and carboplatin. In addition, this agent shows promising activity in bladder, head and neck, esophageal, renal, and cervical carcinomas. Preliminary results of studies in these tumor types are reviewed.

UR - https://www.scopus.com/pages/publications/0036264671

UR - https://www.scopus.com/pages/publications/0036264671#tab=citedBy

U2 - 10.1016/s0093-7754(02)70216-9

DO - 10.1016/s0093-7754(02)70216-9

M3 - Review article

C2 - 12023793

AN - SCOPUS:0036264671

SN - 0093-7754

VL - 29

SP - 50

EP - 53

JO - Seminars in oncology

JF - Seminars in oncology

IS - 2 SUPPL. 5

ER -

Pemetrexed in the treatment of selected solid tumors

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this